Recombinant Anti-Tuberin (phospho S939) antibody [EP1062Y] (ab52962)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP1062Y] to Tuberin (phospho S939)
- Suitable for: WB
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Tuberin (phospho S939) antibody [EP1062Y]
See all Tuberin primary antibodies -
Description
Rabbit monoclonal [EP1062Y] to Tuberin (phospho S939) -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF,IHC-Fr,IHC-P or IP -
Species reactivity
Reacts with: Mouse, Human
Predicted to work with: Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- 3T3 cell lysates (untreated or treated with insulin). WB: SH-SY5Y (Human neuroblastoma epithelial cell) treated with 200nM Okadaic Acid (OA) and 1uM Calyculin A (CA) for 60 min whole cell lysates
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EP1062Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab52962 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Detects a band of approximately 180 kDa (predicted molecular weight: 201 kDa).
|
Notes |
---|
WB
1/1000 - 1/10000. Detects a band of approximately 180 kDa (predicted molecular weight: 201 kDa). |
Target
-
Function
In complex with TSC1, inhibits the nutrient-mediated or growth factor-stimulated phosphorylation of S6K1 and EIF4EBP1 by negatively regulating mTORC1 signaling. Acts as a GTPase-activating protein (GAP) for the small GTPase RHEB, a direct activator of the protein kinase activity of mTORC1. Implicated as a tumor suppressor. Involved in microtubule-mediated protein transport, but this seems to be due to unregulated mTOR signaling. Stimulates weakly the intrinsic GTPase activity of the Ras-related proteins RAP1A and RAB5 in vitro. Mutations in TSC2 lead to constitutive activation of RAP1A in tumors. -
Tissue specificity
Liver, brain, heart, lymphocytes, fibroblasts, biliary epithelium, pancreas, skeletal muscle, kidney, lung and placenta. -
Involvement in disease
Defects in TSC2 are the cause of tuberous sclerosis type 2 (TSC2) [MIM:613254]. TSC2 is an autosomal dominant multi-system disorder that affects especially the brain, kidneys, heart, and skin. It is characterized by hamartomas (benign overgrowths predominantly of a cell or tissue type that occurs normally in the organ) and hamartias (developmental abnormalities of tissue combination). Clinical symptoms can range from benign hypopigmented macules of the skin to profound mental retardation with intractable seizures to premature death from a variety of disease-associated causes.
Defects in TSC2 are a cause of lymphangioleiomyomatosis (LAM) [MIM:606690]. LAM is a progressive and often fatal lung disease characterized by a diffuse proliferation of abnormal smooth muscle cells in the lungs. It affects almost exclusively young women and can occur as an isolated disorder or in association with tuberous sclerosis complex. -
Sequence similarities
Contains 1 Rap-GAP domain. -
Post-translational
modificationsPhosphorylation at Ser-1387, Ser-1418 or Ser-1420 does not affect interaction with TSC1.
Phosphorylation at Ser-939 and Thr-1462 by PKB/AKT1 is induced by growth factor stimulation. -
Cellular localization
Cytoplasm. Membrane. At steady state found in association with membranes. - Information by UniProt
-
Database links
- Entrez Gene: 7249 Human
- Entrez Gene: 22084 Mouse
- Entrez Gene: 24855 Rat
- Omim: 191092 Human
- SwissProt: P49815 Human
- SwissProt: Q61037 Mouse
- SwissProt: P49816 Rat
- Unigene: 90303 Human
see all -
Alternative names
- FLJ43106 antibody
- LAM antibody
- OTTHUMP00000158940 antibody
see all
Images
-
All lanes : Anti-Tuberin (phospho S939) antibody [EP1062Y] (ab52962) at 1/1000 dilution
Lane 1 : SH-SY5Y (Human neuroblastoma epithelial cell) whole cell lysates
Lane 2 : SH-SY5Y (Human neuroblastoma epithelial cell) treated with 200nM Okadaic Acid (OA) and 1uM Calyculin A (CA) for 60 min whole cell lysates
Lane 3 : SH-SY5Y (Human neuroblastoma epithelial cell) treated with 200nM Okadaic Acid (OA) and 1uM Calyculin A (CA) for 60 min whole cell lysates. Then the membrane was incubated with phosphatase.
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Developed using the ECL technique.
Predicted band size: 201 kDa
Observed band size: 180 kDa why is the actual band size different from the predicted?
Exposure time: 90 secondsBlocking/Diluting buffer and concentration: 5% NFDM/TBST.
This image is derived from purified batch.
-
All lanes : Anti-Tuberin (phospho S939) antibody [EP1062Y] (ab52962) at 1/10000 dilution
Lane 1 : 3T3 cell lysate untreated
Lane 2 : 3T3 cell lysate treated with insulin
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 201 kDa
Observed band size: 180 kDa why is the actual band size different from the predicted?
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (3)
ab52962 has been referenced in 3 publications.
- Mallela K et al. Oncogenic role of MiR-130a in oral squamous cell carcinoma. Sci Rep 11:7787 (2021). PubMed: 33833339
- Tang L et al. Electroacupuncture Upregulated Ghrelin in Rats with Functional Dyspepsia via AMPK/TSC2/Rheb-Mediated mTOR Inhibition. Dig Dis Sci 65:1689-1699 (2020). PubMed: 31863340
- Shiono M et al. The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition. Oncogene 27:6690-7 (2008). PubMed: 18695678